Relmada Therapeutics (RLMD) Tops Q1 EPS by 26c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.72), $0.26 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Deutsche Bank Starts Associated British Foods (ABF:LN) (ASBFY) at Hold
• Copart (CPRT) Misses Q4 EPS by 4c